ZyVersa stock to be delisted from Nasdaq

ZyVersa Therapeutics, Inc. reports that the Nasdaq Stock Market plans to delist its common stock following the filing of a Form 25 with the SEC on or about September 18, 2025.

Rhea-AI Filing Summary

ZyVersa Therapeutics, Inc. reports that the Nasdaq Stock Market plans to delist its common stock following the filing of a Form 25 with the SEC on or about September 18, 2025. The delisting will become effective ten days after the Form 25 is filed under Exchange Act Rule 12d2-2.

The company’s common stock was suspended from trading on The Nasdaq Capital Market on July 17, 2025 after failing to regain compliance with Nasdaq’s minimum bid price requirement, and it has been trading on the OTCQB Venture Market under the symbol “ZVSA” since July 28, 2025. ZyVersa states that its common stock will continue trading on the OTCQB without disruption.

Positive

• None.

Negative

• Nasdaq delisting: Nasdaq will file a Form 25 around September 18, 2025 to delist ZyVersa’s common stock after prior suspension for not meeting minimum bid price rules.

Insights

Equity markets and listing standards analyst

Nasdaq delisting moves ZyVersa fully to OTCQB trading.

ZyVersa Therapeutics discloses that Nasdaq will announce the delisting of its common stock and file a Form 25 on or about September 18, 2025, with the delisting effective ten days after that filing. The stock had already been suspended from The Nasdaq Capital Market on July 17, 2025 and has traded on the OTCQB Venture Market under “ZVSA” since July 28, 2025.

The trigger for the Panel’s earlier decision was failure to regain compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2). Moving fully off Nasdaq typically reduces trading visibility and may affect liquidity and institutional ownership, though this document focuses only on the fact of delisting and ongoing OTCQB trading.

The key milestone is the Form 25 filing around September 18, 2025, after which the delisting becomes effective ten days later. Future company reports may provide more detail on how operating plans and capital-raising strategies adapt to trading solely on the OTCQB.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Nasdaq action does ZyVersa Therapeutics (ZVSA) report?

ZyVersa reports that Nasdaq plans to announce the delisting of its common stock and file a Form 25 with the SEC on or about September 18, 2025, with the delisting effective ten days after that filing.

Why were ZyVersa Therapeutics (ZVSA) shares suspended from Nasdaq trading?

The company states that a Nasdaq Hearings Panel determined to delist its securities because ZyVersa failed to regain compliance with the minimum bid price requirements under Listing Rule 5550(a)(2), leading to a trading suspension on July 17, 2025.

Where is ZyVersa Therapeutics (ZVSA) stock currently trading?

ZyVersa’s common stock has been trading on the OTCQB Venture Market under the symbol “ZVSA” since July 28, 2025, and the company states this trading will continue without disruption.

When will the ZyVersa Nasdaq delisting become effective?

The delisting of ZyVersa’s common stock from Nasdaq will become effective ten days after Nasdaq files the Form 25 with the SEC, which is expected on or about September 18, 2025.

Does ZyVersa mention any change to OTCQB trading after the Nasdaq delisting?

No change is indicated; ZyVersa states that its common stock will continue trading on the OTCQB Venture Market without disruption following the Nasdaq delisting.

What forward-looking statements does ZyVersa highlight in this report?

ZyVersa notes that statements about the timing of the delisting are forward-looking and subject to risks and uncertainties discussed in its prior Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/18/2025 - 07:00 AM Learn about SEC filing dates

false 0001859007 0001859007 2025-09-14 2025-09-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 14, 2025

ZYVERSA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41184		86-2685744
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2200 N. Commerce Parkway, Suite 208, Weston, Florida		33326
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (754) 231-1688

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ZVSA		—(1)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

(1) On September 14, 2025, the Nasdaq Stock Market notified ZyVersa Therapeutics, Inc. (the “Company”) of its plans to announce the delisting of the Company’s common stock and file a Form 25 with the Securities and Exchange Commission on or about September 18, 2025. The Company’s common stock is trading on the OTCQB® Venture Market under the symbol “ZVSA.”

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On September 14, 2025, the Nasdaq Stock Market (“Nasdaq”) notified ZyVersa Therapeutics, Inc. (the “Company”) that, on September 18, 2025, it will announce the delisting of the Company’s common stock. The Company’s common stock was suspended from trading on The Nasdaq Capital Market on July 17, 2025, and has been trading on the OTCQB® Venture Market (the “OTCQB”) under the symbol “ZVSA” since July 28, 2025. Nasdaq will file a Form 25 with the Securities and Exchange Commission (the “SEC”) to complete the delisting in accordance with Rule 12d2-2 promulgated under the Securities Exchange Act of 1934, as amended. The delisting will become effective ten days after the Form 25 is filed. The Company’s common stock will continue trading on the OTCQB without disruption.

As previously reported on the Company’s Current Report on Form 8-K filed with the SEC on July 16, 2025, the Company received written notice from the Nasdaq Hearings Panel (the “Panel”) on July 15, 2025, indicating that the Panel had determined to delist the Company’s securities from Nasdaq and that trading in the Company’s securities would be suspended at the open of trading on July 17, 2025, due to the Company’s failure to regain compliance with the minimum bid price requirements under Listing Rule 5550(a)(2).

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Current Report on Form 8-K (“Form 8-K”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the timing of the delisting of the Company’s common stock. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks, uncertainties and other important factors, including those factors discussed under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as updated by the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, in each case as filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this Form 8-K. Any forward-looking statements speak only as of the date of this Form 8-K and are based on information available to the Company as of the date of this Form 8-K, and the Company assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 18, 2025	ZYVERSA THERAPEUTICS, INC.
	/s/ Stephen Glover
	Stephen Glover
	Chief Executive Officer